Cancer Treatment in Sweden - Costs of Drugs, Inpatient and Outpatient Care from 1985 to 1996 and Cost Effectiveness of New Drugs

This study was carried out to investigate the direct costs for treatment of patients with cancer from 1985 to 1996 in Sweden, and to examine health economic effects of changes in treatment pattern. Material for the study was collected from official statistics and from published health economic evalu...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 1998, Vol.37 (5), p.447-453
Main Author: Gunnel Ragnarson Tennvall, Göran Karlsson
Format: Article
Language:English
Subjects:
Ambulatory Care - economics
Androgen Antagonists - economics
Androgen Antagonists - therapeutic use
Antineoplastic agents
Antineoplastic Agents - economics
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy
Cost-Benefit Analysis
Deoxycytidine - analogs & derivatives
Deoxycytidine - economics
Deoxycytidine - therapeutic use
Drug Costs
Filgrastim
Gonadotropin-Releasing Hormone - economics
Gonadotropin-Releasing Hormone - therapeutic use
Granulocyte Colony-Stimulating Factor - economics
Granulocyte Colony-Stimulating Factor - therapeutic use
Humans
Medical sciences
Neoplasms - drug therapy
Neoplasms - economics
Paclitaxel - economics
Paclitaxel - therapeutic use
Pharmacology. Drug treatments
Receptors, Serotonin - drug effects
Receptors, Serotonin, 5-HT3
Recombinant Proteins
Sweden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was carried out to investigate the direct costs for treatment of patients with cancer from 1985 to 1996 in Sweden, and to examine health economic effects of changes in treatment pattern. Material for the study was collected from official statistics and from published health economic evaluations of cancer treatment. Costs for inpatient care decreased during the period, while costs for outpatient care and drugs increased. In total, the direct health care costs for cancer treatment decreased from 1985 to 1996. New drugs registered on the market are often more expensive than the drugs they replace. From a health economic perspective it is not clear, however, that higher drug costs necessarily increase total costs. Further health economic research is needed because many treatment alternatives have not yet been evaluated, and furthermore, because a treatment option can be cost effective in one specific indication but not in another.
ISSN:0284-186X
1651-226X
DOI:10.1080/028418698430395